Received Apr 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | PF44A | LL |
The reporter states that a fifteen-month old child received a BOOSTRIX dose in the left thigh by mistake.; The reporter states that a fifteen-month old child received a BOOSTRIX; This non-serious case was reported by a nurse and described the occurrence of product administered at inappropriate site in a 15-month-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number PF44A) for prophylaxis. On 02-APR-2026, the patient received Boostrix (left thigh) .5 ml. On 02-APR-2026, an unknown time after receiving Boostrix, the patient experienced product administered at inappropriate site (Verbatim: The reporter states that a fifteen-month old child received a BOOSTRIX dose in the left thigh by mistake.) and inappropriate age at vaccine administration (Verbatim: The reporter states that a fifteen-month old child received a BOOSTRIX). The outcome of the product administered at inappropriate site and inappropriate age at vaccine administration were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.